Lombard Odier Asset Management (Europe)’s Alexion Pharmaceuticals ALXN Stock Holding History

Lombard Odier Asset Management (Europe)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,210	Closed	-$338K	–	261
2021 Q1	$338K	Buy	+2,210	New	+$342K	0.02%	160
2020 Q4	–	Sell	-1,753	Closed	-$201K	–	413
2020 Q3	$201K	Buy	+1,753	New	+$189K	0.01%	343
2020 Q2	–	Sell	-2,462	Closed	-$221K	–	298
2020 Q1	$221K	Hold	2,462	–	–	0.02%	258
2019 Q4	$266K	Hold	2,462	–	–	0.02%	322
2019 Q3	$241K	Hold	2,462	–	–	0.02%	336
2019 Q2	$322K	Hold	2,462	–	–	0.03%	268
2019 Q1	$333K	Hold	2,462	–	–	0.03%	239
2018 Q4	$240K	Hold	2,462	–	–	0.02%	296
2018 Q3	$342K	Buy	2,462 +243	+11%	+$30.5K	0.02%	266
2018 Q2	$275K	Hold	2,219	–	–	0.02%	287
2018 Q1	$247K	Sell	2,219 -225	-9%	-$26.9K	0.02%	314
2017 Q4	$292K	Sell	2,444 -350	-13%	-$42.6K	0.02%	300
2017 Q3	$392K	Hold	2,794	–	–	0.02%	265
2017 Q2	$340K	Hold	2,794	–	–	0.02%	280
2017 Q1	$339K	Hold	2,794	–	–	0.02%	262
2016 Q4	$342K	Hold	2,794	–	–	0.12%	219
2016 Q3	$342K	Hold	2,794	–	–	0.12%	235
2016 Q2	$326K	Buy	+2,794	New	+$396K	0.02%	266

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Lombard Odier Asset Management (Europe)'s ALXN Position: Q2 2021 in Review

Lombard Odier Asset Management (Europe) sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,210 shares — an estimated $338K sold.

Lombard Odier Asset Management (Europe) first reported a position in ALXN in Q2 2016 and held it in 18 quarters. The position peaked at $392K in Q3 2017. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Lombard Odier Asset Management (Europe) reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Lombard Odier Asset Management (Europe) sold 2,210 Alexion Pharmaceuticals shares in Q2 2021, an estimated $338K.
Lombard Odier Asset Management (Europe) first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 18 quarters.
Lombard Odier Asset Management (Europe)'s Alexion Pharmaceuticals position peaked at $392K in Q3 2017.
708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Lombard Odier Asset Management (Europe)'s 13F filing for Q2 2021, filed 13 Aug 2021.